Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04466345
Other study ID # 19-6283
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 6, 2021
Est. completion date October 5, 2024

Study information

Verified date May 2023
Source University Health Network, Toronto
Contact Rodrigo B. Mansur, MD, PhD
Phone 416 603 5106
Email rodrigo.mansur@uhn.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).


Description:

This is a 16-week, placebo-controlled, randomized, double-blind, clinical trial, involving 60 overweight individuals with MDD and pre-treatment cognitive dysfunction. Study participants will receive one of the following study interventions in addition to 'standard of care' treatment: once-daily semaglutide, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks; or matching placebo. Participants will be assessed to examine the effect of semaglutide on their cognitive function.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 5, 2024
Est. primary completion date October 5, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Informed consent before study-related activity 2. Individuals between the ages of 18 and 60 who meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for MDD 3. Overweight (i.e. BMI = 25 kg/m2) 4. Below-average (i.e. >1 SD below norm) performance in the Trail Making Test-B (TMTB) Exclusion Criteria: 1. Current, or in the past 4 weeks, treatment with other oral hypoglycemic agents and/or insulin 2. Diagnosis of possible or probable Alzheimer's Disease, Mild Cognitive Impairment, or any other dementia 3. History of neurological disorder, or evidence of neurologic or other physical illness that could produce cognitive deterioration 4. Severe mood episode, defined as a Hamilton Depression Rating Scale (HAMD-17) score of >23 5. Actively suicidal or evaluated as being a suicide risk (operationalized as a score of =3 on HAMD-17 suicide item and/or by clinical assessment). 6. Substance use disorder within 3 months before screening or a positive baseline toxicology screen 7. DSM-5 diagnosis of obsessive compulsive disorder, posttraumatic stress disorder (current or within the last year), or borderline personality disorder as assessed by a study investigator 8. Presence of absolute or relative contraindication to semaglutide (e.g. hypersensitivity to semaglutide, hepatic impairment, renal impairment with chronic kidney disease stage 3 and above, personal or familial history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2) 9. History of diabetic retinopathy 10. History of pancreatitis or pancreatic cancer 11. Presence of clinically unstable general medical illness 12. Pregnancy or breastfeeding women

Study Design


Intervention

Biological:
Semaglutide
3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
Placebo
Semaglutide placebo capsules

Locations

Country Name City State
Canada Toronto Western Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Executive Function Composite Score The primary outcome will be an executive function composite score. This score will be comprised of the Digit Symbol Substitution Test (DSST - number of symbols), the Stroop test (time to completion in the congruent and incongruent conditions), and the Spatial n-back (reaction times and accuracy in four conditions,1-back, 2-back, 3-back, and 4-back). 16 Weeks
Secondary Digit Symbol Substitution Test (DSST) DSST is a neurocognitive test designed to assess motor speed and concentration. 16 Weeks
Secondary Rey Auditory Verbal Learning Test (RAVLT) RAVLT is a neurocognitive test designed to assess verbal learning and memory. 16 Weeks
Secondary Stroop Test The Stroop Test is a neurocognitive test designed to assess the ability to inhibit cognitive interference. 16 Weeks
Secondary Trail Making Test A (TMTA) TMTA is a neurocognitive test designed to assess visual scanning and attention. 16 Weeks
Secondary Perceived Deficits Questionnaire (PDQ) PDQ is used to assess subjective cognitive dysfunction. 16 Weeks
Secondary 36-Item Short Form Health Survey (SF-36) SF-36 is used to assess quality of life. 16 Weeks
Secondary Sheehan Disability Scale (SDS) SDS is used to assess functional impairment in work/school, social life, and family life. 12 Weeks
Secondary Endicott Workplace Productivity Scale (EWPS) EWPS is used to assess workplace productivity. 16 Weeks
Secondary Height Unit: cm 16 Weeks
Secondary Weight Unit: kg 16 Weeks
Secondary fasting glucose - Blood laboratorial marker 16 Weeks
Secondary Diet History Questionnaire III (DHQ) DHQ is a freely available questionnaire used to assess dietary intake (https://epi.grants.cancer.gov/dhq3/). 16 Weeks
Secondary Physical Activity Questionnaire (IPAQ) IPAQ is used to assess physical activity. 16 Weeks
Secondary Pittsburgh Sleep Quality Index (PSQI) PSQI is used to assess sleep quality. 16 Weeks
Secondary Trail Making Test B (TMTB) TMTB is a neurocognitive test designed to assess attention and concentration. 16 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4